½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­ : À¯Çüº°, °Ë»ç Àå¼Òº°, ¿ëµµº°, Áö¿ªº°(2025-2033³â)
Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2025-2033
»óǰÄÚµå : 1660711
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 135 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 115¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 222¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 7.22%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

½ÉÀå ¸¶Ä¿´Â ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿¶ó°íµµ ºÒ¸®¸ç, ½ÉÀåÀÌ ½ºÆ®·¹½º¸¦ ¹Þ°Å³ª ±ÙÀ°ÀÌ ¼Õ»óµÇ¸é Ç÷·ù·Î ¹æÃâµË´Ï´Ù. ÀÌ·¯ÇÑ ¸¶Ä¿¿¡´Â ½É±Ù Æ®·ÎÆ÷´Ñ, Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦(CK), ÇãÇ÷¼º º¯Çü ¾ËºÎ¹Î(IMA), ¹Ì¿À±Û·Îºó µî ´Ù¾çÇÑ Á¾·ùÀÇ È¿¼Ò, È£¸£¸ó, ´Ü¹éÁúÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¸¶Ä¿ÀÇ ÃøÁ¤ ¹× °Ë»ç´Â ½ÉÀå ÇãÇ÷ ¹× ±Þ¼º°ü»óµ¿¸ÆÁõÈıº(ACS)°ú °°Àº ½ÉÀå ÁúȯÀ» Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇöÀç ÀÌ·¯ÇÑ ÁúȯÀÇ À§ÇèÀ» ÆÇ´ÜÇϱâ À§ÇÑ ¼±º° ¹× Áø´Ü ½Ã½ºÅÛÀº ½ÉÀüµµ(ECG)¿Í ÀÓ»ó °æ°ú¸¦ ±â¹ÝÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ºÒÃæºÐÇϸç, ¿ÀÁøÀ̳ª Ä¡·á Áö¿¬À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ½ÉÀå ¸¶Ä¿ °Ë»ç´Â Á¤È®µµ°¡ ³ô°í ¹ßº´ Ãʱ⿡ º´Å¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ¾î Àü ¼¼°èÀûÀ¸·Î ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸¶Ä¿´Â ÀÌ·¯ÇÑ ÁúȯÀÇ ¿¹Èĸ¦ º¸´Ù Á¤È®ÇÏ°Ô ¸ð´ÏÅ͸µÇϰí ȯÀÚ¿¡°Ô °¡Àå È¿°úÀûÀÎ Ä¡·á¸¦ Á¦°øÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ÃËÁø¿äÀÎ:

Áö³­ ¸î ³â µ¿¾È ±Þ¼º½É±Ù°æ»öÁõ(ACS) ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ½ÉÀå ¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ´Ù¾çÇÑ CVDÀÇ Á¶±â Áø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ È¯ÀÚ ¹× ÀÇ·áÁøÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ·¯ÇÑ ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ßÀÇ Ã·´Ü ±â¼úÀ» °³¹ßÇϱâ À§ÇØ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ÅõÀÚÇÏ´Â ¹Î°£ ¹× °ø°ø ±â°üÀÌ ¸¹ÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, °í°¨µµ ½É±Ù Æ®·ÎÆ÷´Ñ i Ç÷¾× °Ë»ç´Â 2Â÷ ½ÉÀ帶ºñ À§ÇèÀÌ ³ôÀº ȯÀÚ¸¦ ½Äº°ÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç°¡ Á¦°øÇÏ´Â ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú, Àú·ÅÇÑ °¡°ÝÀÇ ½ÉÀå ÇöÀå °Ë»çÀÇ °¡¿ë¼º°ú ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ´Ù¸¥ ¿äÀεé Áß ÀϺÎÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : °Ë»ç Àå¼Òº°

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ »ê¾÷ : SWOT ºÐ¼®

Á¦11Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ »ê¾÷ : ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ »ê¾÷ : Porter's Five Forces ºÐ¼®

Á¦13Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ »ê¾÷ : °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global cardiac biomarkers market size reached USD 11.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.

Global Cardiac Biomarkers Market Drivers:

Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.

Key Market Segmentation:

Breakup by Type:

Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.

Breakup by Location of Testing:

Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.

Breakup by Application:

Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cardiac Biomarkers Market

6 Market Breakup by Type

7 Market Breakup by Location of Testing

8 Market Breakup by Application

9 Market Breakup by Region

10 Global Cardiac Biomarkers Industry: SWOT Analysis

11 Global Cardiac Biomarkers Industry: Value Chain Analysis

12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis

13 Global Cardiac Biomarkers Industry: Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â